---
title: In Focus e-report on the future of antibody-based drug
description: In Focus e-report on the future of antibody-based drug
---

[![DDW-Logo](https://info.edifydigitalmedia.com/hs-fs/hubfs/DDW-Logo.png?width=239&height=121&name=DDW-Logo.png "DDW-Logo")](https://www.edifydigitalmedia.com/)

![shutterstock\_1736709881](https://info.edifydigitalmedia.com/hubfs/shutterstock_1736709881.jpg "shutterstock_1736709881")

# In Focus e-report on the future of antibody-based drug

 

![DDW\_InFocus\_Report\_0323\_FrontCover\_200px](https://info.edifydigitalmedia.com/hubfs/DDW_InFocus_Report_0323_FrontCover_200px.jpg "DDW_InFocus_Report_0323_FrontCover_200px")

*The future of anti-body based drugs: Where are the opportunities and what does the future hold?* Thisis a free 16 page e report, available here.

This report

- Provides an overview of the monoclonal antibody (mAbs) industry: market value, key antibody-based drug players, opportunities and the future for the sector
- Explore what’s next for antibody-based drugs and where the opportunity is coming from
- Includes an interview with Bio-Rad’s John Cardone, who shares expertise on the future of antibody-based drug discovery
- Shares significant future trends for the therapeutic antibody market

Key insights:

- The global mAb market size was valued at $185.50 billion in 2021
- Biopharmas originating in China will likely have greater influence on the industry by 2028
- The lessons learned from mAb development for SARS-CoV-2 will likely provide an important platform for the scientific community
- With over 10 biosimilars approved, Argentina and Brazil have the most biosimilar monoclonal antibodies approved in Latin America
  
  *Sponsored by*

*![\_BIO-RAD LOGO](https://info.edifydigitalmedia.com/hs-fs/hubfs/_BIO-RAD%20LOGO.png?width=141&height=62&name=_BIO-RAD%20LOGO.png)*

 

### Download the e-report

## Copyright 2022 Drug Discovery World. All Rights Reserved Privacy Policy & Cookies | Contact | Terms & Conditions